linjc16/ctgov huggingface dataset:
Skills of Home Helpers for a Better Quality of Life for Adults With Huntington's Disease Living at Home

Study Overview
=================
Brief Summary
-----------------
Huntington's disease often brings together 3 types of symptoms at one time or another of the disease during its evolution: motor, cognitive and psychiatric. Management requires comprehensive and multidisciplinary health, social or medico-social support. Its development generates additional difficulties for professionals who very often qualify this disease as very complex because it leads to a deep and severe impairment of physical and intellectual capacities. The sick person gradually loses their autonomy and becomes dependent for the acts of daily life, hence the choice of this disease for our study. Our study is focused on the quality of life at home of patients followed by the Angers Reference Center, expert on neurogenetic pathologies. Studies focusing on patients' quality of life at home have so far never been undertaken for a rare neurodegenerative disease like Huntington's disease.

Official Title
-----------------
Skills of Home Helpers for a Better Quality of Life for Adults With Huntington's Disease Living at Home

Conditions
-----------------
Quality of Life

Intervention / Treatment
-----------------
* Other: interview


Participation Criteria
=================
Eligibility Criteria
-----------------
Selection Criteria: Patient group : Genetic diagnosis of Huntington's disease Symptomatic patient Patient living at home Person able to carry out the interviews provided for in the study Caregiver group : Person, defined within the meaning of the CNSA (National Solidarity Fund for Autonomy) as a natural caregiver, not concerned himself by the risk of developing the disease person able to carry out the interviews provided for in the study Home Helper group : - Professionals working at home with Huntington's disease patients employed by home help service providers.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br> | Other: interview<br>* interview<br>|
| Caregivers<br> | Other: interview<br>* interview<br>|
| Home help<br> | Other: interview<br>* interview<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify and compare the expectations and needs of patients with Huntington's disease, their caregivers, and home helpers, in terms of home support, based on interviews |  | One day |
Trodat 1 SPECT and Dopamine Polymorphism

Study Overview
=================
Brief Summary
-----------------
The study population will include 100 parkinsonian patients in early stage of disease, with total duration not exeeding 5 years. The patients will undergo neurologic examination and evaluation of disease severity using the unified PD rating scale. Subsequently a brain SPECT will be performed using Tc-99m-Trodat1.

Detailed Description
-----------------
The study sample will include 100 Israeli Jewish patients with early idiopathic PD who were not treated with anti-parkinson drugs. The clinical diagnosis will be based on the criteria of the United Kingdom Parkinson Disease Society Brain Bank.5 All patients will undergo Tc-99m-Trodat1 SPECT. The severity of the motor symptoms will be assessed with the Unified PD Rating Scale (UPDRS). Genomic DNA is extracted from peripheral blood leukocytes for genetic analysis.

Official Title
-----------------
Association of Polymorphism in Genes Associated With Control of Dopamine Levels in Parkinson's Disease and Tc-99m-Trodat-1 SPECT Imaging.

Conditions
-----------------
Parkinson Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inclusion criteria were early Israeli PD patients Of jewish origin, males or females Undergoing DAT-scan examination in Wolfson medical center at early stage of disease, accompanied by a UPDRS evaluation at that stage,performed by a trained neurologist Patients did not use any type of anti-parkinsonian drug type, at time of DAT-scan performance and UPDRS evaluation DNA sample was obtained Patients were able to sign an informed consent form to participate in this study. Exclusion Criteria: Patients were excluded if they features secondary parkinsonism or if they were treated with medications that block dopamine receptors.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Parkinson<br>Early onset of disease | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease severity versus genetic polymorphism | Correlation of disease severity with polymorphism and with striatal affinity to the DAT ligand. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of PD compared to specific striatal DAT activity as measures by Tc-99m Trodat SPECT. | For each striatal ROI, mean counts will be measured, and specific TRODAT uptake will be calculated, according to the following formula: Specific TRODAT uptake = (mean activity in ROI - mean Activity in occipital cortex) / mean Activity in occipital cortex). | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Severity of disease
Study of Light Treatment and Laser Treatment for Melasma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the efficacy of light treatment and laser treatment for melasma. These treatment options have not been thoroughly explored in the treatment of melasma. By studying the effect of different treatments, a better treatment plan may be developed for people with melasma.

Detailed Description
-----------------
The objective of this study is to determine the efficacy of light treatment and laser treatment for melasma. These treatment options have not been thoroughly explored in the treatment of melasma. By studying the effect of different treatments, a better treatment plan may be developed for people with melasma.

Official Title
-----------------
A Randomized, Rater-blinded, Split-face Comparison of the Efficacy of Intense Pulse Light vs. Q-switched Nd:Yag Laser for the Treatment of Melasma.

Conditions
-----------------
Melasma

Intervention / Treatment
-----------------
* Procedure: Light Treatment
* Procedure: Laser Treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of melasma lesion measuring at least 4 square centimeters. Age 18-75 years. Good health. Willingness and ability to understand and provide informed consent for participation in the study. Ability to communicate with the investigator. Must be willing to forgo other treatment options for melasma during the course of the study. Exclusion Criteria: Inability to understand the protocol or to give informed consent. Mental illness. Under 18 years of age and over 75 years of age. Laser treatment in the last 6 months before enrollment. Isotretinoin within the past year. Lidocaine allergy. History of herpes simplex viral infection. Concurrent active disease to facial area (i.e acne). Bleeding disorder. History of abnormal wound healing. History of abnormal scarring.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Light therapy | Procedure: Light Treatment<br>* Light treatment applied to half of the face at each study visit<br>|
| Experimental: 2<br>Laser Treatment | Procedure: Laser Treatment<br>* Laser treatment applied to half of the face at each study visit<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Melasma Area and Severity Index |  | 20 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety |  | 20 weeks |
Efficacy of Bupivacain Local Infiltration for the Management of Pain During Cesarean Section

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate the effect of local administration of bupivacain in the cesarean section incision for postoperative pain control, using the visual analogue pain scale (VAS) and assessing the need for rescue analgesia after surgery.

Official Title
-----------------
Efficacy of Bupivacain Local Infiltration for the Management of Pain During Cesarean Section. Randomized, Single Blind, Controlled Trial

Conditions
-----------------
Pain, Postoperative

Intervention / Treatment
-----------------
* Drug: Bupivacain
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gestational age ≥ 36 weeks Elective cesarean section Transverse segmental caesarean section Pfannenstiel type Spinal anesthesia Maternal age 18 to 45 years Any gravaparity Patient ASA I or II Exclusion Criteria: Any patient who does not meet the inclusion criteria. Emergency cesarean section History of chronic or neuropathic pain Patient with cardiopulmonary disease Known allergies to the drugs used in the study Patient who does not wish to participate in the study
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bupivacaine<br>20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue. | Drug: Bupivacain<br>* 20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.<br>|
| Placebo Comparator: Placebo<br>20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue. | Drug: Placebo<br>* 20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post operative pain | Level of pain described using a Visual Analogue Scale (VAS) Lower value: 0 (no pain) Higher value: 10 (worst pain possible) | 72 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Need for rescue medication | Number of participants that required an additional analgesic for pain control | 72 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cesarean section, Postoperative Pain, Bupivacain
INTERACTION, Monitoring of Stroke Patients in Hospital and Home Environment

Study Overview
=================
Brief Summary
-----------------
Clinical assessment and monitoring of balance and arm function in stroke patients with sensor based measurement, in clinical and home environment.

Official Title
-----------------
Proof of Concept Study of the INTERACTION Technology, Monitoring of Stroke Patients in Hospital and Home Environment

Conditions
-----------------
Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: 18 or above Previous Stroke in the personal history Able to walk 10 meters. A walking aid (unilateral or bilateral) is permitted Able to walk without special shoes Able to raise the arm against gravity Able to read and understand questionnaires and able to execute commands Able and willing to participate in the study Singed Informed Consent Exclusion Criteria: Contraindications on ethical grounds (vulnerable persons) known or suspected non-compliance, drug or alcohol abuse, Severe aphasia Severe dementia Severe depression Relevant medical disease or increased risk of rehospitalization Severe sensory deficits Severe neglect

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| proof of concept |  | 3 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lower limb, monitoring, assessment, sensor, upper limb
T-116_Procera-Bridge Zirconia - A Clinical Study

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to evaluate the clinical performance of Procera® Bridge Zirconia veneered with NobelRondo Zirconia.

Detailed Description
-----------------
The study was designed to be an open, 5-year, prospective, multi-center clinical post-market study. The objectives of this clinical study were that industrial centrally produced 3- or 4-unit bridges of yttrium-oxide partially-stabilized (Y-TZP) zirconia (Procera Zirconia) in combination with the veneering ceramic material NobelRondo will show sufficient CDA ratings (90% R+S) and a sufficient survival rate after 1 and 5 years.

Official Title
-----------------
Procera-Bridge Zirconia - A Clinical Study

Conditions
-----------------
Partial Edentulism

Intervention / Treatment
-----------------
* Device: Procera® Bridge Zirconia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible Indication: same indication as for metal supported bridges Obtained informed consent from the patient Exclusion criteria Currently known alcohol, drug or medication abuse, judged by the investigator, which might influence the follow-up program Patients where a bridge part connection area of 3 mm of diameter is not possible to obtain (short clinical crowns) Mobility of the abutment teeth exceeding grade I Patients with pathologic pocket formation at abutment teeth Patients with complete dentures in the opposing jaw Patients with a removable partial denture in the same jaw

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Procera® Bridge Zirconia<br>Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible. | Device: Procera® Bridge Zirconia<br>* Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success Rate of Bridge Procera Bridge Zirconia | The CDA index (1) is Romeo or Sierra at delivery and remains so up to 1 year post loading. | prosthesis delivery, 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success Rate of Bridge Procera Bridge Zirconia | The CDA index (1) is Romeo or Sierra at delivery and remains so 5 year post loading. | prosthesis delivery, 5 years |
Nasal Resonance Change After Endoscopic Endonasal Transsphenoidal Skull Base Surgery: Analysis of Quality of Voice

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine nasal resonance change after endoscopic endonasal transsphenoidal skull base surgery. Furthermore, the quality of voice is assessed, also.

Conditions
-----------------
Voice Quality, Endoscopic Pituitary Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent endoscopic endonasal transsphenoidal skull base surgery Exclusion Criteria: Patients under 18 year Patients cannot following command including loss of conscious Patients cannot speak including patient on tracheostomy tube Patients who has nasal tumor, nasal polyp, sinusitis Patients who has cleft lip cleft palate or submucosal cleft Patients who underwent adenotonsillectomy or palatoplasty in same setting with endoscopic pituitary surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nasal resonance change after endoscopic endonasal transsphenoidal surgery which was assessed by computer speech lab |  | Two years |
Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides

Study Overview
=================
Brief Summary
-----------------
The Systemic Necrotizing Vasculitides (SNV) encompass a group of rare diseases which include Wegener's Granulomatosis (WG), Churg-Strauss Syndrome (CSS), Microscopic polyangiitis (MPA)and Polyarteritis nodosa (PAN). Common histological findings are inflammation with fibrinoid necrosis of the small vessels and sporadic or absent immune-deposits. The gold standard therapy for SNV is currently represented by the association of Cyclophosphamide and Prednisone. The limits of this approach are the high frequency of recurrent disease and an increased incidence of malignancy and infections. The aim of the present study is to compare the efficacy of Methotrexate vs Cyclophosphamide for Remission Maintenance in SNV.

Official Title
-----------------
Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial.

Conditions
-----------------
Wegener's Granulomatosis, Churg-Strauss Syndrome, Microscopic Polyangiitis, Polyarteritis Nodosa

Intervention / Treatment
-----------------
* Drug: Methotrexate
* Drug: Cyclophosphamide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of clinically active SNV Life-expectancy > 1 year Written informed consent Exclusion Criteria: Creatinine clearance < 10 ml/min/1.73 mq Aminotransferase levels more than twice the upper limit of the normal range HBsAg positivity anti-HCV Ig and HCV-RNA positivity HIV positivity Active malignancies Coexistence of connective tissue disease Prednisolone, cyclophosphamide or methotrexate hypersensitivity Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br>Cyclophosphamide | Drug: Cyclophosphamide<br> <br> |
| Experimental: B<br>Methotrexate | Drug: Methotrexate<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time from remission to relapse |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence rate |  |  | 
| Therapy-related toxicity |  |  | 
| Hospitalization rate |  |  | 
| Mortality |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vasculitis, Cyclophosphamide, Methotrexate, Systemic Necrotizing Vasculitides